首页> 外文期刊>Clinical oncology >Survival in high-grade glioma: a study of survival in patients unfit for or declining radiotherapy.
【24h】

Survival in high-grade glioma: a study of survival in patients unfit for or declining radiotherapy.

机译:高度神经胶质瘤的生存:一项不适合放疗或放射治疗下降的患者的生存研究。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To determine the survival of patients with high-grade glioma (HGG) and a poor prognosis in terms of age or performance status managed with best supportive care alone. METHODS: An analysis of survival was carried out on 123 patients with HGG declining or judged unfit to receive radiotherapy, on the basis of age or performance status, between February 1998 and October 2003. Karnofsky performance status (KPS), biopsy or resection or no surgery, attendance at clinic and reason for not receiving radiotherapy were prospectively recorded. RESULTS: Of the 123 patients, three were excluded from the analysis, as no outcome data were available. Median age was 66 years (range 29-91 years), and median KPS was 50 (range 30-100). All 120 patients included had died at the time of analysis. Overall median survival was 68 days (95% CI 56-85), range 2-294 days and interquartile range 35-123 days. Median survival of 22 patients declining radiotherapy was 75 days (95% CI 53-123), of 98 patients unfit for radiotherapy67 days (95% CI 48-88); non-significant difference P = 0.36. Median survival of 26 patients undergoing biopsy was 95 days (95% CI 66-123), of 56 undergoing surgical resection 74 days (95% CI 47-93), and of 38 receiving no surgical intervention 59 days (95% CI 47-70); non-significant difference P = 0.16. CONCLUSION: For patients with HGG and a poor prognosis, in terms of age or performance status managed with best supportive care, survival is short. Survival may be too short to benefit from radiotherapy and possibly surgery.
机译:目的:确定仅通过最佳支持治疗就可治疗的高度神经胶质瘤(HGG)的患者的生存或年龄或性能状况不良的预后。方法:根据年龄或工作状况,对1998年2月至2003年10月之间123例HGG下降或被判定不适合接受放射治疗的HGG患者进行了生存分析。Karnofsky表现状态(KPS),活检或切除或无前瞻性地记录了手术,门诊就诊以及未接受放射治疗的原因。结果:在123例患者中,有3例被排除在分析之外,因为没有可用的结局数据。中位年龄为66岁(范围为29-91岁),中位KPS为50(范围为30-100)。在分析时,所有120名患者均已死亡。总体中位生存期为68天(95%CI 56-85),范围2-294天,四分位间距35-123天。 22名放射治疗下降的患者中位生存期为75天(95%CI 53-123),98名不适合放射治疗的患者67天(95%CI 48-88);非显着性差异P = 0.36。 26名接受活检的患者中位生存期为95天(95%CI 66-123),56名接受手术切除的患者74天(95%CI 47-93),38名未接受手术干预的患者59天(95%CI 47-93) 70);非显着性差异P = 0.16。结论:对于HGG且预后较差的患者,就年龄或工作状态进行最佳支持治疗而言,生存期较短。生存时间可能太短,无法从放射治疗和可能的手术中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号